Argent BioPharma Limited

OTCPK:RGTL.F Stock Report

Market Cap: US$5.1m

Argent BioPharma Management

Management criteria checks 3/4

Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.83 years. total yearly compensation is A$417.06K, comprised of 92.8% salary and 7.2% bonuses, including company stock and options. directly owns 17.12% of the company’s shares, worth $870.01K. The average tenure of the management team and the board of directors is 2.2 years and 4 years respectively.

Key information

Roby Zomer

Chief executive officer

AU$417.1k

Total compensation

CEO salary percentage92.8%
CEO tenure8.8yrs
CEO ownership17.1%
Management average tenure2.2yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to Argent BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$417kAU$387k

-AU$18m

Mar 31 2024n/an/a

-AU$17m

Dec 31 2023n/an/a

-AU$17m

Sep 30 2023n/an/a

-AU$19m

Jun 30 2023AU$354kAU$354k

-AU$21m

Mar 31 2023n/an/a

-AU$22m

Dec 31 2022n/an/a

-AU$23m

Sep 30 2022n/an/a

-AU$22m

Jun 30 2022AU$629kAU$422k

-AU$20m

Mar 31 2022n/an/a

-AU$19m

Dec 31 2021n/an/a

-AU$18m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021AU$481kAU$281k

-AU$16m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$16m

Jun 30 2020AU$440kAU$290k

-AU$19m

Dec 31 2019n/an/a

-AU$18m

Sep 30 2019n/an/a

-AU$14m

Jun 30 2019AU$495kAU$330k

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$498kAU$334k

-AU$8m

Compensation vs Market: Roby's total compensation ($USD260.32K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Roby's compensation has increased whilst the company is unprofitable.

CEO

Roby Zomer (44 yo)

8.8yrs

Tenure

AU$417,064

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Leadership Team

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.8yrsAU$417.06k17.12%
$ 870.0k
Igor Bluvstein
Chief Financial Officerless than a yearno datano data
Yifat Steuer
Deputy CEO & COO2.2yrsno data2.06%
$ 104.6k
Shachar Shimony
Group General Counselno datano datano data
Masa Oblak
People Managerno datano datano data
Amir Polak
Chief Pharmaceutical Development Officerno datano data1.09%
$ 55.5k
Sabina Suljakovic
Chief Quality and Commercial Officer4.3yrsno datano data
Nadya Lisovoder
Chief Medical Officerno datano datano data
Sasha Friedman
Deputy CEOno datano datano data
Yair Tal
Chief Information Security Officerno datano datano data
Rowan Harland
Company Secretary1.8yrsno datano data
Ana Oblak
Group Financial Controllerno datano datano data

2.2yrs

Average Tenure

Experienced Management: RGTL.F's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.8yrsAU$417.06k17.12%
$ 870.0k
Ross Grant Walker
Chairman of Strategic Advisory Boardno dataAU$32.00kno data
Uri Kramer
Member of Strategic Advisory Board8.4yrsno datano data
Layton Mills
Independent Non-Executive Director1.5yrsAU$61.92kno data
Wendyl D'Souza
Member of Medical Advisory Board6.4yrsno datano data
Daniel Robinson
Non-Executive Independent Directorless than a yearAU$41.92kno data
Shlomo Sadoun
Member of Advisory Boardless than a yearno datano data

4.0yrs

Average Tenure

Experienced Board: RGTL.F's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:56
End of Day Share Price 2024/12/02 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Argent BioPharma Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Salvatore Gaetano VerdolivaCanaccord Genuity
Robin DavisonCapital Network by Proactive Investors
Maxim JacobsEdison Investment Research